Payment overview · 2025
General Payments
$1,076.81
65 reported records · 14 companies
Healthcare provider profile · identity verified
Kimberly Barbolla, DO
Allopathic & Osteopathic Physicians|Internal Medicine · MARSHALL, TX · NPI 1437132081
Verified facts
What the public records show
CMS Open Payments records show Kimberly Barbolla, DO received $1,076.81 in general payments during 2025 across 65 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xyosted by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 330 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $268.00 | 24.9% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $179.35 | 16.7% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.44 | 15.6% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.46 | 15.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $86.74 | 8.1% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $48.15 | 4.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.10 | 3.2% | 2 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $32.54 | 3.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $20.28 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.37 | 1.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.21 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.98 | 1.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.31 | 1.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.88 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,076.81 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $268.00 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $150.66 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $130.87 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $92.42 | 16 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $92.42 | 16 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $86.93 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.89 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.68 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $48.15 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.06 | 2 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $32.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 330 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 66 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
131 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
66 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
330 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 653 | 153 |
| Pantoprazole Sodium | Pantoprazole Sodium | 602 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 131 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 517 | 80 |
| Gabapentin | Gabapentin | 470 | 102 |
| Losartan Potassium | Losartan Potassium | 380 | 89 |
| Potassium Chloride | Potassium Chloride | 378 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 97 |
| Jardiance | Empagliflozin | 330 | 40 |
| Lisinopril | Lisinopril | 323 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 307 | 76 |
| Trazodone Hcl | Trazodone Hcl | 292 | 69 |
| Meloxicam | Meloxicam | 262 | 65 |
| Sertraline Hcl | Sertraline Hcl | 247 | 46 |
| Furosemide | Furosemide | 244 | 62 |
| Carvedilol | Carvedilol | 241 | 66 |
| Montelukast Sodium | Montelukast Sodium | 235 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 231 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 49 |
| Omeprazole | Omeprazole | 216 | 46 |
| Buspirone Hcl | Buspirone Hcl | 211 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 48 |
| Donepezil Hcl | Donepezil Hcl | 188 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 47 |
| Metformin Hcl | Metformin Hcl | 173 | 40 |
| Tramadol Hcl | Tramadol Hcl | 160 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 153 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 147 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 143 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 34 |
| Eliquis | Apixaban | 132 | 25 |
| Myrbetriq | Mirabegron | 131 | 13 |
| Bupropion Xl | Bupropion Hcl | 128 | 30 |
| Memantine Hcl | Memantine Hcl | 124 | 28 |
| Mirtazapine | Mirtazapine | 121 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 115 | 24 |
| Famotidine | Famotidine | 115 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 47 |
| Allopurinol | Allopurinol | 114 | 25 |
| Ibandronate Sodium | Ibandronate Sodium | 114 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 46 |
| Cephalexin | Cephalexin | 108 | 77 |
| Alendronate Sodium | Alendronate Sodium | 106 | 20 |
| Celecoxib | Celecoxib | 106 | 32 |
| Divalproex Sodium | Divalproex Sodium | 105 | 18 |
| Ozempic | Semaglutide | 105 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 99 | 22 |
| Farxiga | Dapagliflozin Propanediol | 96 | 23 |
| Levetiracetam | Levetiracetam | 96 | 16 |
| Metformin Hcl Er | Metformin Hcl | 93 | 30 |
| Simvastatin | Simvastatin | 92 | 26 |
| Nifedipine Er | Nifedipine | 78 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 20 |
| Pregabalin | Pregabalin | 70 | 20 |
| Venlafaxine Hcl | Venlafaxine Hcl | 68 | 14 |
| Kerendia | Finerenone | 66 | 11 |
| Benazepril Hcl | Benazepril Hcl | 65 | 16 |
| Glimepiride | Glimepiride | 65 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 14 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 16 |
| Fentanyl | Fentanyl | 64 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 62 | suppressed |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 61 | 22 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 56 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 56 | suppressed |
| Linzess | Linaclotide | 53 | 13 |
| Propranolol Hcl | Propranolol Hcl | 52 | suppressed |
| Atenolol | Atenolol | 51 | 13 |
| Fenofibrate | Fenofibrate | 49 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 16 |
| Latanoprost | Latanoprost | 46 | suppressed |
| Spironolactone | Spironolactone | 46 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Ezetimibe | Ezetimibe | 44 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 15 |
| Topiramate | Topiramate | 44 | 11 |
| Nitroglycerin | Nitroglycerin | 42 | 27 |
| Olanzapine | Olanzapine | 42 | suppressed |
| Prednisone | Prednisone | 42 | 24 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Methocarbamol | Methocarbamol | 39 | 11 |
| Dutasteride | Dutasteride | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Vascepa | Icosapent Ethyl | 38 | suppressed |
| Lactulose | Lactulose | 37 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | suppressed |
| Nystatin | Nystatin | 37 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 14 |
| Progesterone | Progesterone, Micronized | 37 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 33 |
| Baclofen | Baclofen | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 28 |
| Promethazine Hcl | Promethazine Hcl | 33 | 14 |
| Scopolamine | Scopolamine | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | 11 |
| Glipizide | Glipizide | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 23 |
| Methadone Hcl | Methadone Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Folic Acid | Folic Acid | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Valsartan | Valsartan | 26 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 19 |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Xifaxan | Rifaximin | 24 | suppressed |
| Caplyta | Lumateperone Tosylate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 17 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Alogliptin | Alogliptin Benzoate | 21 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nyamyc | Nystatin | 21 | suppressed |
| Sulfasalazine | Sulfasalazine | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Nystop | Nystatin | 20 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Trospium Chloride | Trospium Chloride | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Fluorometholone | Fluorometholone | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Xyosted | Testosterone Enanthate | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diovan | Valsartan | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Flavoxate Hcl | Flavoxate Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,076.81 · 65 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, FARXIGA, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, XYOSTED, ZEPBOUND, bio-ConneKt | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error